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In eukaryotic cells, the inactivation of the cyclic nucleotide signal
depends on a complex array of cyclic nucleotide phosphodiester-
ases (PDEs). Although it has been established that multiple PDE
isoenzymes with distinct catalytic properties and regulations co-
exist in the same cell, the physiological significance of this remark-
able complexity is poorly understood. To examine the role of a PDE
in cAMP signaling in vivo, we have inactivated the type 4 cAMP-
specific PDE (PDE4D) gene, a mammalian homologue of the Dro-
sophila dunce. This isoenzyme is involved in feedback regulation of
cAMP levels. Mice deficient in PDE4D exhibit delayed growth as
well as reduced viability and female fertility. The decrease in
fertility of the null female is caused by impaired ovulation and
diminished sensitivity of the granulosa cells to gonadotropins.
These pleiotropic phenotypes demonstrate that PDE4D plays a
critical role in cAMP signaling and that the activity of this isoen-
zyme is required for the regulation of growth and fertility.
In organisms as diverse as bacteria and mammals, changes inthe intracellular concentration of the second messenger cAMP
control a wide range of cell functions including entry and exit
from the cell cycle, differentiation, metabolism, and gene ex-
pression. Similar to that shown for the Ca21-dependent signaling
pathway (1), it has been hypothesized that the intensity and
duration of the cAMP signals determine the specificity of
cellular responses to different stimuli (2). The pattern of intra-
cellular cAMP accumulation depends on the activity of cyclic
nucleotide phosphodiesterases (PDEs). These enzymes are reg-
ulated during hormone and neurotransmitter stimulation (3, 4)
in concert with other mechanisms that control cAMP synthesis
(5) and have profound effects on cAMP levels and cell responses
(3, 4, 6, 7).
To date, at least 20 PDE genes and almost 50 distinct PDE
proteins have been described in mammalian cells (8). These
isoenzymes are characterized by different biochemical and ki-
netic properties, subcellular localization, and mechanisms of
regulation. However, the reason a cell requires the expression of
such a large array of PDEs with an overlapping function is poorly
understood. It has been speculated that each isoenzyme serves
slightly different roles and its expression is necessary for the
specificity of the cAMP signaling or for signal compartmental-
ization. Here we have addressed the question of this apparent
redundancy of the cAMP-degrading machinery by studying the
effect of inactivating a single PDE gene.
With some rare exceptions, pharmacological inhibition of
PDE activity results in an increased signaling through the
cAMP-dependent pathway (9), an effect that mimics the stim-
ulation by hormones and neurotransmitters. Although this idea
may hold true for short-term pharmacological manipulations, in
vivo long-term cell homeostasis and differentiation is more likely
impaired by the disruption of the PDE system. If the expression
of distinct PDE isoenzymes is indeed required for proper cAMP
signaling, the inactivation of one PDE should produce a loss,
rather than a gain of function. This view is supported by the
phenotype caused by mutations in the Drosophila melanogaster
dunce PDE. Flies deficient in this PDE display impairments of
the central nervous system and reproductive functions (10). In
the same vein, natural mutations inactivating a PDE expressed
in the retina cause retinal degeneration (11).
Although only one dunce PDE has been described in the fly,
four orthologous genes (PDE4A, PDE4B, PDE4C, and PDE4D)
are present in mice (12), rats (13), and humans (14), and the
encoded proteins share considerable homology in their catalytic
and regulatory domains (4, 8, 15). The evolutionary significance
for this gene duplication is unknown. In vitro and in vivo studies
have demonstrated that one of type 4 cAMP-specific PDEs
(PDE4D) is activated either through protein kinase A-depen-
dent phosphorylation (16) or through regulation of transcription
(17). This dual regulation in endocrine, inflammatory, and
neuronal cells determines the intensity and the duration of the
cAMP stimulus and promotes adaptive changes such as desen-
sitization (4), at least in vitro.
To dissect the function of different PDEs in vivo, a PDE4 gene
widely expressed in different organs of the mouse was inactivated
by homologous recombination. The pleiotropic phenotypes pro-
duced demonstrate that inactivation of the PDE4D gene causes
major loss of cell functions. Thus, we demonstrate that a PDE4D
plays a nonredundant role in cyclic nucleotide signaling in vivo.
Materials and Methods
Construction of PDE4D Targeting Vector. Three overlapping clones
corresponding to exons 6–11 of the PDE4D gene were isolated
by screening a 129svj lambda FIXII mouse genomic library
(Stratagene). A 1.7-kb SacI–ClaI fragment 59 to exon 8 and a
9.6-kb EcoRI–EcoRV fragment 39 to exon 10 were isolated and
subcloned into a knockout plasmid to generate targeting vectors
(Fig. 1A). The knockout plasmid, a gift of D. Repaske, Univer-
sity of Cincinnati, uses pBluescript II SK as a backbone and
contains a PGK-hprt cassette (for positive selection) and a
pMC1-tk cassette (for negative selection) subcloned at HindIII
and KpnI sites, respectively. The targeting vector was con-
structed by blunt-end ligation of the two genomic fragments at
BamHI and ClaI sites of the knockout plasmid so that the hprt
and tk genes were in the opposite orientation to the PDE4D
genomic sequence (targeting vector I, Fig. 1 A). An additional
targeting vector also was constructed with the hprt and tk genes
in the same orientation as the PDE4D gene (targeting vector II,
not shown). In the constructs thus created, the hprt gene
substituted for a 3.2-kb genomic fragment that contains exons
8–10 of the gene. The constructs were confirmed by restriction
mapping, and the ligation sites were directly validated by DNA
sequencing.
Production of PDE4D-Deficient Mice. The targeting vectors were
linearized with NotI and electroporated into E14TG2a embry-
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onic stem (ES) cells (18). Homologous recombinant ES clones
were screened by Southern blot analysis. ES cells from positive
clones were microinjected into C57BLy6 blastocysts and im-
planted into pseudopregnant females. The resulting chimeras
were mated to C57BLy6 mice to produce F1 progeny with
heterozygous genotype (PDE4D1/2). Further crosses between
the PDE4D1/2 mice yielded F2 generation homozygous mu-
tants (PDE4D2/2) with a mixed 129yOla and C57BLy6 back-
ground. Genotyping of animals was performed on DNA from
tail tips by Southern blot analysis. Of 10 chimeras generated
from the two PDE4D targeting vectors, three transmitted the
disrupted allele to the offspring. Here, we report the data
obtained from the mice that were generated from two chime-
ras of targeting vector I.
Southern Blot Analysis. DNA prepared from embryonic stem cells
and tail tips was digested with XhoI and EcoRI, fractionated by
agarose gel electrophoresis, transferred to a nylon membrane
(ICN), and then hybridized with the 0.22-kb PCR-generated
probe that flanked the 59 homology region (Fig. 1 A). Expected
sizes for wild-type and mutant PDE4D are 5.5 kb and 4.6 kb,
respectively.
Reverse Transcription–PCR and Southern Blot Analysis of mRNA.
First-strand cDNA was synthesized from 400 ng of poly(A)1
RNA isolated from adult mouse cortex and cerebellum, followed
by PCR amplification. PCR primers used were 59-CGGAACT-
TGCCTTGATGT-39 and 59-ACAGAGGCGTTGTGCTTG-39
located in exons 8 and 10, respectively. The PCR product was
analyzed by Southern blot as described above, except that the
membrane was hybridized with an exon 9-specific oligonucleo-
tide probe (59-CACATGAATCTGCTGGC-39).
Western Blot Analysis. Cortex and cerebellum were dissected from
adult mouse brain and immediately homogenized as described
(19). After centrifugation at 16,000 3 g for 20 min, the super-
natant was immunoprecipitated with a PDE4D-specific mAb,
M3S1, a PDE4A-specific polyclonal antibody, AC55, or a
PDE4B-specific polyclonal antibody, K118 (19). The immuno-
precipitated PDE4D, PDE4A, and PDE4B proteins were further
detected by Western blot analysis using a PDE4D-specific mAb,
F34–8F4, AC55, and K118, respectively. The immunoprecipita-
tion and Western blotting procedures were carried out as
described (19).
PDE Assay. Pituitaries, ovaries, and cerebella were dissected from
animals and were homogenized as described above. Aliquots of
the homogenates were assayed for total PDE activity as well as
rolipram-insensitive PDE activity by incubation in the absence or
presence of 10 mM rolipram. The PDE assay was performed
according to the method of Thompson and Appleman (20) as
detailed previously (21). The rolipram-sensitive rolipram-
insensitive activity (PDE4 activity) was obtained by subtracting
the RI activity from the total activity. Protein concentration was
determined by using the Bradford method (22).
Test of Fertility and Ovulation. Immature (20–35 days of age) or
adult cycling females were injected s.c. with 5 units of pregnant
mare serum gonadotropin (PMSG, Calbiochem). After 48 h,
mice received 5 units i.p. of human chorionic gonadotropin
(hCG, Goldline Labs, Fort Lauderdale, FL) to induce ovulation.
After 24 h, the ovulated oocytes were retrieved from the ampulla
of the oviduct and counted. The ovaries of these mice were fixed
with 4% paraformaldehyde. Eight to 10-micron sections were
prepared from OCT-embedded ovaries and stained with hema-
toxylin and eosin according to standard procedures.
cAMP Response to hCG in Granulosa Cells in Vitro. The cAMP
response of granulosa cells to hCG was measured according to
the procedure described previously (21). Briefly, adult mice were
treated with PMSG for 44 h, and the granulosa cells were
collected by puncturing the large antral follicles under a ste-
reomicroscope. After centrifugation, the cells were placed in 1
ml of Hepes-buffered McCoy’s 5A (GIBCOyBRL) culture me-
dium in the absence or presence of hCG (100 ngyml, National
Institute of Diabetes and Digestive and Kidney Diseases), fol-
licle-stimulating hormone (250 ngyml, National Institute of
Diabetes and Digestive and Kidney Diseases), or forskolin (100
mM). To terminate the incubation, cultured cells were centri-
fuged at 1,000 3 g for 10 min, and 0.1% trichloroacetic acid in
Fig. 1. Targeted disruption of the mouse PDE4D locus. (A) Strategy used for
targeting the PDE4D gene. The structure of the wild-type PDE4D gene in the
region containing exons 7–11 (Top), the targeting vector (Middle), and the
homologous recombinant (Bottom) are shown. The targeting vector derived
from pBluescript SK1 (pBS-SK) contains 59 and 39 flanking regions of homol-
ogy (open boxes) and is designed to replace the ClaI–EcoRI fragment that
contains exons 8–10 with a PGK-hprt cassette. Both hprt and tk genes are in
the opposite transcriptional orientation as PDE4D. The probe used for South-
ern blot analysis of EcoRIyXhoI-digested genomic DNA is indicated. The ex-
pected sizes of EcoRI–EcoRI (5.5 kb) and EcoRI–XhoI (4.6 kb) fragments are
reported as double arrows. (B) Southern blot analysis of genomic DNA isolated
from PDE4D1/1, PDE4D1/2, and PDE4D2/2 mouse tail tips, digested with EcoRI
and XhoI and hybridized to the probe shown in A. (C) Expression of PDE4D
mRNA in mouse brain. Reverse transcription–PCR for poly(A)1 RNA extracted
from pooled cortex and cerebellum of PDE4D1/1, PDE4D1/2, and PDE4D2/2
mice was carried out as described in Materials and Methods. The 59 and 39
primers used in the PCR are specific to the exon 8 and exon 10 sequence of
PDE4D, respectively. The 444-bp PCR fragment was detected by Southern blot
analysis using an exon 9-specific oligonucleotide probe. (D) Expression of
PDE4D, PDE4A, and PDE4B proteins in mouse brain. Cortexes and cerebella
dissected from PDE4D1/1, PDE4D1/2, and PDE4D2/2 mice were homogenized
and immunoprecipitated as described in Materials and Methods. The PDE4D
(4D3 and 4D4), PDE4A (4A1 and 4A5), and PDE4B1 proteins were detected by
Western blot analysis as described in Materials and Methods. A mixture of
recombinant PDE4D3 and PDE4D4 (R) was loaded for control.











95% ethanol was added to the cell pellet. After 30-min extrac-
tion, the supernatant was recovered by centrifugation at 3,000 3
g for 10 min and dried under vacuum. The cAMP levels were
determined by RIA (23).
Results
Targeted Disruption of the PDE4D Gene. Of the four PDE4 loci
present in the mouse, we report here the inactivation of the
PDE4D gene. The PDE4D locus is composed of at least 18 exons
distributed over 150 kb of genomic DNA. Multiple transcrip-
tional units and alternate splicing generate five transcripts that
encode five distinct proteins with divergent amino termini (8).
Because of the presence of multiple promoters and to ensure an
inactivation of all PDE4D variants, exons encoding the catalytic
domain were chosen as the target for recombination (Fig. 1 A).
Exons 8–10 of the gene contain sequences highly conserved
among PDEs, and point mutations or deletions in the region
produce catalytically inactive PDE4D proteins (24).
Genotyping of the F2 generation mice demonstrated the
predicted shift in the size of a restriction fragment from 5.5 to
4.6 kb (Fig. 1B). The PDE4D mRNA levels were measured by
reverse transcription–PCR followed by Southern blot analysis.
Although a PDE4D mRNA was readily detected in wild-type
(PDE4D1/1) mice, a significant decrease of mRNA and no
mRNA was observed in the PDE4D1/2 and PDE4D2/2 mice,
respectively (Fig. 1C). The loss of PDE4D mRNA was reflected
in the absence of PDE4D protein expression. In the brain, where
PDE4D is expressed at high levels, none of the PDE4D variants
could be detected in the PDE4D2/2 mice after immunoprecipi-
tation and Western blot analysis using antibodies that recognize
epitopes at the carboxyl terminus (Fig. 1D) and at the amino
terminus of PDE4D (data not shown). Conversely, the products
of the PDE4A and PDE4B genes were expressed at a compa-
rable level in the PDE4D1/1 and PDE4D2/2 mice (Fig. 1D).
Effects of the Disrupted PDE4D Gene on PDE Activity. To determine
whether the inactivation of the PDE4D gene is associated with
a decrease in PDE activity, cAMP hydrolysis was measured in
extracts of cerebella, pituitaries, and ovaries in the absence or
presence of rolipram, a PDE4-specific inhibitor (Fig. 2). Total
PDE activity was decreased in the PDE4D2/2 mice in all regions
examined. This decrease was entirely the result of a decrease in
rolipram-sensitive activity, and no significant changes could be
observed for the rolipram-insensitive activity (Fig. 2). Although
activity decreased to different extents depending on the organ,
similar findings were obtained with cerebral cortex, hippocam-
pus, liver, lung, and spleen (data not shown). It also was observed
that in some tissues, such as pituitary and cerebellum, only a
minimal decrease in PDE activity was detected in the heterozy-
gous mice. Because we have shown that PDE4D expression is
regulated by cAMP (25), inactivation of one PDE4D allele may
cause a cAMP-dependent compensatory increase in transcrip-
tion from the wild-type allele.
Viability of the PDE4D2/2 Mice. Genotyping of F2 mice at 30 days
of age (D30) demonstrated a distortion of the Mendelian
inheritance of the null allele, with only 13.8%, rather than the
expected 25%, of PDE4D2/2 mice recovered (Table 1). A similar
result also was obtained for the mice derived from targeting
vector II, ruling out the possibility that phenotype is caused by
spurious rearrangements at the site of recombination. Further
genotyping of D0 (newborn), D7, and D14 pups demonstrated
that most PDE4D2/2 mice died between D0 and D14 (Table 1).
This phenotype was exacerbated when the PDE4D null allele was
transferred to an 129svj background (9.5% homozygous null
recovered at D30). Thus, more than 40% of the PDE4D2/2 mice
died within 4 weeks after birth.
Growth Retardation of the PDE4D2/2 Pups. Surviving PDE4D2/2
pups had retarded growth, exhibiting a 30–40% decrease in body
weight at 1–2 weeks after birth (Fig. 3). Growth rate returned to
normal after 2 weeks, but the weight of the adult mice remained
lower than normal (Fig. 3B). This phenotype again was con-
firmed in the mice that were derived from targeting vector II
(data not shown). The decrease in body weight was caused by a
proportional decrease in muscle and bone mass and internal
organ weight with the exception of cortex and cerebellum (data
not shown). These two parts of the brain had weights comparable
to those of wild-type littermates. The PDE4D1/2 mice had a
phenotype similar to the PDE4D1/1 mice, essentially excluding
the possibility that truncated PDE4D produced from the dis-
rupted allele exerts dominant negative effects. The decrease in
weight of the PDE4D2/2 mice was associated with a decrease in
circulating insulin-like growth factor I (IGF-I) levels (ngyml;
PDE4D1/2 mice: 372 6 35, n 5 15; PDE4D2/2 mice: 213 6 45,
n 5 6; P , 0.05; measured at D15), suggesting that the GH-IGF-I
axis is impaired in immature mice deficient in PDE4D.
Effects of the Disrupted PDE4D Gene on Female Fertility. Mating of
PDE4D2/2 females and males produced smaller litter sizes than
the control PDE4D1/1 littermates. To further determine
whether, in addition to decreased viability, reduced fertility of
the homozygous pairs contributes to the small litter size,
PDE4D2/2 females and males were mated to PDE4D1/1 mice
Fig. 2. PDE activity in different mouse organs. Pituitaries, ovaries, and cere-
bella were dissected from PDE4D1/1, PDE4D1/2, and PDE4D2/2 mice and were
homogenized as described in Materials and Methods. Aliquots of the homog-
enates were assayed for total PDE activity (T) or rolipram-insensitive (RI) PDE
activity in the absence or presence of 10 mM rolipram, respectively. The
rolipram-sensitive (RS) activity was obtained by subtracting the RI value from
the T value. Data are the mean 6 SEM (n $ 3 miceygenotype). Significant
differences in the total activity and in the RS activity between PDE4D1/1 and
PDE4D2/2 mice were determined by t test and are indicated by single (*, P ,
0.05) and double asterisks (**, P , 0.005).






N % N % N %
D0 93 24 25.8 40 43 29 31.2
D7 69 19 27.5 33 47.8 17 24.6
D14 65 17 26.2 38 58.5 10 15.4
D30 347 94 27.1 205 59.1 48 13.8*
Mice were produced by mating F1 heterozygous males and females.
*P , 0.001 by x2-test, with the expected genotype ratio of 25% of 1y1, 50%
of 1y2, and 25% of 2y2.
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and the litter size was determined on D0 (Fig. 4). Because the
pups generated by these matings are all heterozygous, the litter
size should no longer be affected by the decreased viability of the
PDE4D2/2 litters. Although PDE4D2/2 males produced a sim-
ilar number of pups to PDE4D1/1 males, PDE4D2/2 females
produced significantly fewer pups, demonstrating that a reduced
fertility of the female is a major cause for the small litter size
from homozygous mating.
Using in situ hybridization in the ovary, we have shown that
PDE4D mRNA is expressed at high levels in the mural granulosa
cells, but not in the cumulus or theca cells or in the oocytes (26).
Furthermore, follicle-stimulating hormone and luteinizing hor-
mone regulate PDE4 activity in vitro (21), and in vivo studies
have demonstrated that PDE4 activity changes in synchrony with
the follicular cycle (27). These findings suggest that an impaired
follicular function is the cause of the reduced fertility in
PDE4D2/2 females. This possibility was investigated by mea-
suring the ovulation rate in PDE4D2/2 females after superovu-
lation induction. In contrast to the wild-type pubertal litter-
mates, the PDE4D2/2 females (D20 or D28–32) yielded few
oocytes in response to PMSG-hCG stimulation (Fig. 5A). The
D28–32 null mice have a greater weight than the D20 wild-type
mice, ruling out the possibility that the ovulation failure is a
consequence of the immaturity of the mice. Although the
ovulation rate of adult cycling PDE4D2/2 females was increased
in comparison to pubertal mice (Fig. 5A), more than 50% of the
oocytes recovered from the ampulla of the oviducts showed clear
signs of degeneration with disrupted metaphase or oocyte
fragmentation (data not shown). In contrast, degeneration was
only occasionally observed in the wild-type females.
Histological examination of the ovaries from the D20 super-
ovulated mice demonstrated that there was a major increase in
the number of follicles with oocytes entrapped (Fig. 5B), con-
firming a defect in ovulation. Some of these follicles have
undergone luteinization on the basis of their morphological
appearance (Fig. 5B). Conversely, the ovaries from adult super-
ovulated PDE4D2/2 mice were grossly normal, with all stages of
follicular maturation present.
When oocytes of adult PDE4D2/2 mice were removed from
the antral follicles and cultured in vitro, no major defect was
observed and all oocytes resumed meiosis and were arrested in
metaphase II (data not shown). This arrest was maintained for
at least 24 h, indicating that the degeneration of the oocyte
observed in vivo is not caused by a deficit in mos (28) or M-phase
promoting factorycytostatic factor, both required for maintain-
ing the meiotic arrest (29). This finding, together with the
observation that PDE4D is not expressed in the oocytes, indi-
cates that the degeneration is not caused by a primary defect in
the oocyte but rather by an altered granulosa cell function in the
PDE4D2/2 mice. To test this possibility, granulosa cells isolated
from PMSG-treated PDE4D1/2 and PDE4D2/2 mice were
cultured in the absence or presence of hCG, and the intracellular
cAMP accumulation was measured. Granulosa cells derived
from the PDE4D2/2 mice displayed a moderate increase in basal
cAMP levels (P 5 0.08, Fig. 6). Surprisingly, in spite of a
Fig. 3. Growth of PDE4D-deficient mice. (A) Comparison of a PDE4D2/2
mouse (Lower) and a control littermate (Upper) at D34. (B) Growth curves of
PDE4D1/1 (■), PDE4D1/2 (F), and PDE4D2/2 (‚) mice. Each point represents the
mean 6 SEM (n 5 3–99 miceygenotype).
Fig. 4. Female fertility of PDE4D-deficient mice. The litter size from each
mating pair was determined at the day of birth. The number of mating pairs
in each group is from left to right 11, 9, 13, and 17. Data are the mean 6 SEM.
P , 0.001, PDE4D2/2 females versus wild-type females determined by ANOVA.











decrease in the rolipram-sensitive PDE activity in granulosa cells
from the null mice (pmolymin per mg protein, PDE4D1/2:
4.74 6 0.25; PDE4D2/2: 3.02 6 0.39, n 5 3; P , 0.05), a
significant reduction in response to hCG was observed with a
50% decrease in cAMP accumulation detected after 1 h (Fig. 6).
A similar decrease in cAMP accumulation was observed when
follicle-stimulating hormone was used to stimulate the
PDE4D2/2 granulosa cells, whereas the response to forskolin
was not affected (data not shown). This latter finding indicates
that the machinery involved in the cAMP synthesis is not
affected in the granulosa cells of the null mice. A detailed time
course study of hCG stimulation showed no major changes in the
temporal pattern of cAMP accumulation (data not shown). An
impaired granulosa cell response to gonadotropins was further
indicated by the finding that uterine weight after PMSG treat-
ment in the adult PDE4D2/2 mice is consistently lower than that
of heterozygous mice (PDE4D1/2 mice: 98.56 6 2.57 mg, n 5 20;
PDE4D2/2 mice: 74.28 6 6.24 mg, n 5 8, P 5 0.005).
Discussion
With the targeted disruption of the PDE4D gene, we have
demonstrated that PDE4D plays a unique and nonredundant
role in the cell. Loss of its function cannot be compensated for
by any of the cognate PDE4s or members of other PDE families
expressed. Thus, inactivation of PDE4D has a wide array of
pleiotropic phenotypes, including growth retardation and reduc-
tion in viability and female fertility, demonstrating a critical and
indispensable role of this enzyme and its regulations in cell
homeostasis. Moreover, inactivation of a single PDE4 gene
results in altered cAMP signaling and loss of functions in the cell.
Female mice deficient in PDE4D display a reduced fertility with
more than a 50% decrease in litter size. All of the data accumulated
point to a defect in the granulosa cell function as the underlying
cause of the infertility. Gonadotropin responses including cAMP
accumulation in granulosa cells, estrogen production measured as
uterine weight, and ovulation rate all were decreased in the PDE4D
null mice, suggesting that granulosa cell differentiation is disrupted
after the inactivation of PDE4D. The consequent reduced number
of ovulated oocytes and their degeneration are sufficient to account
for the reduced fertility of the adult PDE4D2/2 females. Even
though the superovulation protocol used in our studies eliminates
a possible pituitary contribution to the ovulation phenotype, pitu-
itary contribution to the reduced fertility of the adult cannot be
ruled out at this time.
Although inactivation of PDE4D does not cause a complete
arrest of follicular development, a significant decrease in the
ovulation process was evident at all ages studied. This phenotype
is similar to that produced by targeted disruption of other genes
expressed in granulosa cells, including the progesterone recep-
tor, estrogen receptor b, transcriptional factor CyEBPb
Fig. 5. Ovulation of PDE4D-deficient mice. (A) Ovulation rate (oocytesy
mouse) of mice at different ages of development. Wild-type (1y1) and
homozygous null (2y2) mice were treated with PMSG and hCG as described
in Materials and Methods. Ovulated oocytes were recovered from the ampulla
of the oviducts. Data are the mean 6 SEM. PDE4D2/2 mice are significantly
different from PDE4D1/1 mice with P , 0.001 (analyzed by ANOVA). The gray
area within the bar represents the degenerated oocytes recovered in the adult
mice. Numbers in the brackets indicate the number of mice used in each group.
(B) Histological appearance of ovaries from pubertal PDE4D2/2 mice (Upper,
316; Lower, 352). Mice were treated for superovulation, and ovaries were
dissected, fixed, sectioned, and stained. Luteinized follicles with trapped
oocytes are indicated by arrowheads.
Fig. 6. cAMP response to hCG stimulation in granulosa cells. Granulosa cells
isolated from antral follicles of the PMSG-treated mice were cultured in the
absence (basal) or presence of 100 ngyml hCG. After 1-h incubation, the
intracellular cAMP accumulation was measured by RIA. Data are the mean 6
SEM (n 5 4 independent experiments each carried out in triplicate). The
difference between PDE4D1/2 and PDE4D2/2 mice in response to hCG is
significant (P , 0.001 determined by paired t test, *).
12002 u www.pnas.org Jin et al.
(CCAATyenhancer-binding protein b), aromatase, cyclin D2,
and cyclooxygenase II (30). A common property of these genes
is that they all are induced by gonadotropins via activation of the
cAMP signaling pathway, opening the possibility that their
expression is altered in the PDE4D null mice where the inacti-
vation of PDE4D disrupts cAMP signaling.
It should be emphasized that in spite of the fact that PDE
activity is reduced in granulosa cells of the PDE4D2/2 mice,
rather than increased, the cAMP response to gonadotropin was
significantly reduced. This apparent paradox can be reconciled
by hypothesizing that PDE4D regulation in granulosa cells has
a protective effect on responsiveness, and that inactivation of this
PDE4D negative feedback causes a permanent desensitized state
of the gonadotropin signal transduction. For instance, a chronic
increase in cAMP resulting from the PDE4D inactivation may
produce a condition similar to that produced by the targeted
disruption of the RIIb regulatory subunit of protein kinase A
(31). In this latter case, loss of RII subunit also causes a decrease,
rather than an increase, in the C subunit activity because of an
accelerated degradation. Moreover, an altered duration and
intensity of a transient cAMP accumulation may have a major
impact in the ovarian follicle, where cAMP is thought to diffuse
through gap junctions between granulosa cells themselves and
between granulosa cells and oocytes (32). In addition to com-
promising the normal dynamics of follicular differentiation, an
altered half-life and diffusion of cAMP may abrogate differences
between mural and cumulus granulosa cell functions that are
crucial for oocyte maturation and ovulation (32). The reduced
viability of the oocytes that are ovulated in PDE4D2/2 adult
mice probably is caused by the uncoupling of granulosa cell and
oocyte maturation. In view of our finding that PDE4 inhibitors
cause oocyte maturation in follicle culture in the absence of
gonadotropin stimulation (26), it is possible that resumption of
meiosis in the PDE4D null mice is no longer synchronized with
final maturation of the follicle.
Our findings are strikingly similar to the phenotype caused by
mutations in the Drosophila dunce PDE. The defect in egg
deposition in the mutant flies is caused by an impaired function
of both the egg and nursing cells (33). Thus, PDE4D plays a
critical role in the ovarian follicle, and this function is conserved
from Drosophila to mammals.
In endocrine glands, receptoryG protein-activating mutations
produce a phenotype of hyperstimulation or end-organ auton-
omous function (34). A similar phenotype would be predicted by
inactivation of a PDE gene because the decrease in the rate of
cAMP degradation would be expected to cause increased cAMP
signaling and chronic stimulation of the endocrine gland. This,
however, was not the case in the PDE4D-deficient mice. These
mice present a phenotype of disrupted cAMP signaling in
granulosa cells rather than hyperfunction. Similar decreased
sensitivity or altered cAMP signaling may explain the reduced
growth of the PDE4D2/2 mice. We could speculate that an
altered cAMP accumulation in somatotrophs of the pituitary
disrupts the growth hormone releasing hormone-growth hor-
mone axis as it has been demonstrated for the litylit mouse (35).
Thus, the phenotype of the PDE4D null mice opens the possi-
bility that endocrine disorders characterized by end-organ re-
sistance are caused by inherited recessive mutations that disrupt
the PDE4D function.
Measurements of the PDE activity in different organs from
PDE4D2/2 mice demonstrate a marked decrease in the roli-
pram-sensitive activity. Together with the observed phenotypes,
these findings demonstrate that other PDE4s expressed in
mammals cannot compensate for the loss of PDE4D and that the
function of this gene does not completely overlap with the
function of other PDE4s. Differences in expression, regulation,
and localization of the different PDE4s account for these
divergent functions (4). This observation has important phar-
macological implications. Because PDE4 inhibitors are being
developed as anti-inflammatory agents for asthma, chronic
obstructive pulmonary disease, and other inflammatory disor-
ders, our data hold promise for specific inhibition of a single
PDE4 gene product as a viable strategy for pharmacological
intervention (36).
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